or Try an Advanced Search...

    Technical Analysis for CADL - Candel Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 12.95 -7.50% -1.05
    CADL closed up 30.84 percent on Wednesday, May 15, 2024, on 25 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Up Up Up
    Historical CADL trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing High Bullish -7.50%
    Expansion Breakout Bullish Swing Setup -7.50%
    Wide Range Bar Range Expansion -7.50%
    New 52 Week High Strength -7.50%
    Wide Bands Range Expansion -7.50%
    Above Upper BB Strength -7.50%
    Overbought Stochastic Strength -7.50%
    Up 3 Days in a Row Strength -7.50%
    Upper Bollinger Band Touch Strength -7.50%
    NR7 Range Contraction 21.03%
    Older End-of-Day Signals for CADL ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 1 hour ago
    New 52 Week High about 1 hour ago
    Down 5% about 1 hour ago
    Down 3% about 1 hour ago
    Down 2 % about 1 hour ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CADL Chart by TradingView
    Basic chart:

    Profile

    Candel Therapeutics, Inc. Description

    Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Drugs Immunotherapy Surgery Tumor Cancer Immunotherapy Chemotherapy Radiation Pancreatic Cancer Metastases

    Is CADL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Candel Therapeutics GAAP EPS of -$0.28
    May 14 Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
    Apr 25 Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
    Apr 19 How Is The Market Feeling About Candel Therapeutics?
    Apr 15 Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
    Apr 12 Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
    Apr 11 Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment
    Apr 11 Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
    Apr 9 Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
    Apr 6 Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded
    See more CADL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.28
    52 Week Low 0.66
    Average Volume 6,823,301
    200-Day Moving Average 2.15
    50-Day Moving Average 5.11
    20-Day Moving Average 8.17
    10-Day Moving Average 10.09
    Average True Range 1.26
    RSI (14) 81.13
    ADX 64.97
    +DI 51.46
    -DI 4.28
    Chandelier Exit (Long, 3 ATRs) 10.49
    Chandelier Exit (Short, 3 ATRs) 8.84
    Upper Bollinger Bands 12.70
    Lower Bollinger Band 3.63
    Percent B (%b) 1.14
    BandWidth 111.10
    MACD Line 1.85
    MACD Signal Line 1.51
    MACD Histogram 0.3412
    Fundamentals Value
    Market Cap 404.88 Million
    Num Shares 28.9 Million
    EPS -1.10
    Price-to-Earnings (P/E) Ratio -12.73
    Price-to-Sales 1334.04
    Price-to-Book 1.59
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 19.33
    Resistance 3 (R3) 18.83 16.56 18.44
    Resistance 2 (R2) 16.56 15.20 16.81 18.15
    Resistance 1 (R1) 15.28 14.36 15.92 15.78 17.85
    Pivot Point 13.00 13.00 13.32 13.25 13.00
    Support 1 (S1) 11.72 11.64 12.36 12.22 10.15
    Support 2 (S2) 9.45 10.80 9.70 9.85
    Support 3 (S3) 8.17 9.45 9.56
    Support 4 (S4) 8.67